

Anti-CD147 (Meplazumab), Humanized Antibody

02/21

CATALOG NO.: **A2290-50 (50 µg)**
 A2290-100 (100 µg)

BACKGROUND DESCRIPTION: This research-grade biosimilar is a humanized antibody that binds and inhibits CD147. CD147, also known as basigin, is a transmembrane glycoprotein of the immunoglobulin superfamily which acts as a surface receptor involved in tumor development, malaria, and bacterial and viral infections. CD147 has recently been implicated in SARS-CoV-2, wherein the viral spike proteins target the CD147 surface receptor. The original humanized monoclonal antibody is currently being investigated as a combinatorial therapy in patients with pneumonia associated with COVID-19.

ALTERNATE NAMES: Basigin (BSG); 5F7; SLC7A11; EMMPRIN; TCSF

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1-kappa

SOURCE: CHO cells

IMMUNOGEN: Human CD147


FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C. Avoid repeated freeze-thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user



Direct ELISA shows that Anti-CD147 (Meplazumab), Humanized Antibody can bind to human CD147. EC50 = 67.52 ng/mL

RELATED PRODUCTS:

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (Cat. No. A1097)
 Anti-BSG Antibody (Cat. No. A2101)
 Anti-CD6 (Itolizumab), Humanized Antibody (Cat. No. A2164)
 Anti-IL-17 α (Ixekizumab), Humanized Antibody (Cat. No. A2149)
 Anti-ACE2 Antibody (Cat. No. A2072)
 Anti-IL-1 β (Canakinumab), Human IgG1 Antibody (Cat. No. A2144)
 Anti-SARS-CoV-2 RBD Antibody (Clone# CV30) (Cat. No. A2285)

FOR RESEARCH USE ONLY! Not to be used on humans.